Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia
Satellos Bioscience Given Go-ahead for Phase 1 Clinical Trial With SAT-3247 in Australia
Satellos Bioscience獲准在澳洲進行SAt-3247的一期臨床試驗。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊